Abstracts Archive - Page 2243 of 2425 - ACR Meeting Abstracts

Abstract Number: 30 • 2013 ACR/ARHP Annual Meeting
Gene Expression Profiling Analysis Of Human B-Cell Subsets In Health and Systemic Lupus Erythematosus
Chungwen Wei¹, Edward Ramos², Norm Allaire³, Suzanne Szak³, Susan Kalled³, Ann Ranger³ and Ignacio Sanz¹, ¹Rheumatology, Emory University, Atlanta, GA, ²Biology, Emory University, Atlanta, GA, ³Biogen Idec Inc, Cambridge, MA
Background/Purpose: SLE is an autoimmune disease, which exhibits multiple B cell abnormalities including expanded populations of plasmablasts and DN memory cells as well as a…
Abstract Number: 32 • 2013 ACR/ARHP Annual Meeting
Understanding The Stimulatory Pathways Responsible For Naïve B Cell Activation In Systemic Lupus Erythematosus
Emily Blalock¹, Chris Scharer², Scott Jenks¹, Jeremy Boss² and Ignacio Sanz³, ¹Allergy, Immunology, and Rheumatology, Emory University School of Medicine, Atlanta, GA, ²Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, ³Allergy, Immunology and Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Systemic lupus erythematosus (SLE) is a recurrent autoimmune disease characterized by multiple B cell abnormalities, including the activation of naïve B cells. However, gaps…
Abstract Number: 33 • 2013 ACR/ARHP Annual Meeting
B Cell Receptor Signaling As A Potential Clinical Parameter In Lupus
Michael Faludi¹, Christian A. Pineau², Evelyne Vinet¹, Ann E. Clarke³, Sasha Bernatsky⁴, Joyce Rauch² and Emil P. Nashi⁵, ¹McGill University Health Center, Montreal, QC, Canada, ²Rheumatology, McGill University Health Center, Montreal, QC, Canada, ³Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, ⁴Division of Clinical Epidemiology, McGill University Health Center, Montreal, QC, Canada, ⁵Immunology and Rheumatology, McGill University Health Center, Montreal, QC, Canada
Background/Purpose: B cells are central to SLE. Signaling through the B cell receptor (BCR) controls critical processes at various stages of B cell development. Murine…
Abstract Number: 34 • 2013 ACR/ARHP Annual Meeting
Dichotomous Responses Of Human Systemic Lupus Erythematosus B Cell Subsets To B Cell Receptor Stimulation
Franziska Matzkies¹, Anthony DeFranco², Andrew J. Gross³, Maria Dall'era⁴ and Michelle Hermiston⁵, ¹Medicine- Rheumatology, University of California, San Francisco, San Francisco, CA, ²Microbiology & Immunology, University of California, San Francisco, San Francisco, CA, ³Medicine, University of California, San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵Pediatrics, Hematology/Oncology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Autoantibody production is a hallmark of Systemic Lupus Erythematosus (SLE), supporting a central role for B cells in disease pathogenesis. Prior studies have demonstrated…
Abstract Number: 35 • 2013 ACR/ARHP Annual Meeting
Defective Regulatory Function Of Granzyme B-Producing B Cells In Patients With Systemic Lupus Erythematosus
Naoko Ueki, Hiroaki Niiro, Shun-ichiro Ota, Hirofumi Tsuzuki, Siamak Jabbarzadeh-Tabrizi, Yuri Hirosaki, Kumiko Noda, Naoyasu Ueda, Atsushi Tanaka, Masahiro Ayano, Sho Ueda, Satomi Hisamoto, Daisuke Oryoji, Mitsuteru Akahoshi, Yojiro Arinobu, Hiroshi Tsukamoto, Takahiko Horiuchi and Koichi Akashi, Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Background/Purpose: The efficacy of B-cell depletion therapy highlights a pathogenic role of B cells in autoimmune diseases. In certain conditions, elimination of B cells can…
Abstract Number: 36 • 2013 ACR/ARHP Annual Meeting
IFN-α Induces Altered Transitional B Cell Signaling and Function In Systemic Lupus Erythematosus
Joan E. Wither¹, Nan-Hua Chang², Timothy Li³, Julie Kim⁴, Carolina Landolt-Marticorena⁵, Paul R. Fortin⁶, Dafna D. Gladman⁷ and Murray B. Urowitz⁸, ¹1E420/Div of Rheumatology, Toronto Western Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²Genetics and Development, Toronto Western Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Genetics and developmental biology, Toronto Western Hospital, Toronto, ON, Canada, ⁴Toronto Western Hospital, Toronto, ON, Canada, ⁵Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁶Medicine, Centre de Recherche du Chu de Québec et Université Laval, Quebec City, QC, Canada, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Previous experiments suggest that the B cells of lupus patients are hyper-responsive to B cell receptor engagement resulting in increased tyrosine phosphorylation and Ca2+mobilization. …
Abstract Number: 37 • 2013 ACR/ARHP Annual Meeting
Follicular Entry Of Lymphotoxin-Expressing B Cells Via Type I Interferon Disrupts Marginal Zone Barrier Integrity and Exacerbates Systemic Autoimmunity
Hao Li¹, Hui-Chen Hsu², Qi Wu³, Jun Li³, PingAr Yang³, Yang-Xin Fu⁴ and John D. Mountz⁵, ¹Dept. Med - Immunology/Rheumatology division, University of Alabama at Birmingham, Birmingham, AL, ²Birmingham VA Medical Center, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Pathology, The University of Chicago, Chicago, IL, ⁵Dept of Med/Rheumatology Div, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Marginal zone macrophages (MZMs), a small subset of specialized splenic macrophages located in the MZ, act as final follicular entry barrier to clear apoptotic…
Abstract Number: 38 • 2013 ACR/ARHP Annual Meeting
Use Of An In Vitro Whole Blood Depletion ASSAY To Compare The Efficacy Of B CELL Depleting Agents In Patients With Systemic LUPUS Erythematosus
Venkat Reddy¹, Geraldine Cambridge², D.A. Isenberg³, Mark Cragg⁴ and Maria Leandro⁵, ¹Rheumatology, University College London, London, United Kingdom, ²Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ³Centre for Rheumatology Research, University College London, London, United Kingdom, ⁴Antibody and Vaccine group, Cancer Sciences Unit, Faculty of Medicine, Southampton University, Southampton, United Kingdom, ⁵Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Variability in clinical response to B-cell depletion therapy (BCDT) with the anti-CD20mAb rituximab (RTX) has been well described in Systemic Lupus Erythematosus (SLE). Poor…
Abstract Number: 11 • 2013 ACR/ARHP Annual Meeting
Catastrophic Antiphospholipid Syndrome (CAPS): Clinical, Immunologic Features, and Outcome Of 441 Patients From The “CAPS Registry”
Ignasi Rodriguez¹, Gerard Espinosa² and Ricard Cervera³, ¹1Department of Autoimmune Diseases, Fellow, Barcelona, Spain, ²Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Barcelona, Spain, ³Hospital Clinic, Barcelona, Spain
Background/Purpose: To analyze the clinical and laboratory features as well as the precipitating factors, treatment and outcome of patients with catastrophic antiphospholipid syndrome (CAPS). Methods:…
Abstract Number: L15 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety of CT-P13 (Infliximab Biosimilar) over Two Years in Patients with Ankylosing Spondylitis: Comparison Between Continuing with CT-P13 and Switching from Infliximab to CT-P13
Won Park¹, Pedro Miranda², Marek Brzosko³, Piotr Wiland⁴, Sergio Gutierrez-Ureña⁵, Helena Mikazane⁶, Yeon-Ah Lee⁷, Svitlana Smiyan⁸, Mie-Jin Lim¹, Vladimir Kadinov⁹, Carlos Abud-Mendoza¹⁰, YoungKi Son¹¹, Dae-Hyun Yoo¹² and Jürgen Braun¹³, ¹Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ²Universidad de Chile and Centro de Estudios Reumatologicos, Santiago de Chile, Chile, ³Department of Rheumatology and Internal Diseases, Department of Rheumatology and Internal Diseases Pomeranian Medical University in Szczecin, Szczecin, Poland, ⁴Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, ⁵Antiguo Hospital Civil de Guadalajara, Guadalajara, Mexico, ⁶Outpatient Clinic 'ORTO', Riga, Latvia, ⁷Division of Rheumatology, Department of Internal Medicine, Kyung Hee University, Seoul, South Korea, ⁸Municipal Institution of Ternopil Regional Council "Ternopil University Hospital", Ternopil, Ukraine, ⁹Multiprofile Hospital for Active Treatment 'Sv. Marina', Varna, Bulgaria, ¹⁰Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosyi, Mexico, ¹¹CELLTRION, Incheon, South Korea, ¹²Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ¹³PsAID taskforce, EULAR, Zurich, Switzerland
Background/Purpose: CT-P13 is an infliximab (INX) biosimilar recently approved by the European Medicine Agency. PLANETAS was a 54-week (wk) randomized double-blind parallel group multicenter Phase…
Abstract Number: L21 • 2013 ACR/ARHP Annual Meeting
Celastrol, a Triterpene from Tripterygium Wilfordii, Inhibits Neutrophil Extracellular Trap Formation
Christopher D. Koehn¹, Yangsheng Yu², Yinshi Yue², Song Li², Michelene P Hearth-Holmes³, Geoffrey M Thiele³, Ted R. Mikuls⁴, James R. O'Dell⁵, Lynell W. Klassen⁶, Zhixin Zhang² and Kaihong Su², ¹Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁴Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁵Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁶Dept of Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: , Neutrophils provide the frontline of defense against invading pathogens. However, neutrophils also contribute to the development of autoimmune diseases. Recent studies suggest that…
Abstract Number: 1 • 2013 ACR/ARHP Annual Meeting
Anti-â2GP1- Domain-1 Antibodies Are a Marker Of APS Severity
Nancy Agmon-Levin¹, Luciana Seguro², Cristina Rosário³, Michael Mahler⁴, Mariele Gatto⁵, Nir Tomer⁶, Elaine P. Leon⁷, Andrea Doria⁸, László Kovács⁹, Nathalie Costedoat-Chalumeau¹⁰, Boris Gilburd¹¹ and Yehuda Shoenfeld¹², ¹The Zabludowicz Center for Autoimmune Diseases, Tel-Hashomer, Israel, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Internal Medicine Department, Hospital de Pedro Hispano, Rua Dr. Eduardo Torres Matosinhos, Porto, Portugal, ⁴Research, INOVA Diagnostics, San Diego, CA, ⁵Department of Medicine-DIMED, University of Padova, Padova, Italy, ⁶The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel, ⁷Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁸Division of Rheumatology, University of Padova, Padova, Italy, ⁹Department of Rheumatology, University of Szeged, Szeged, Hungary, ¹⁰Internal Medicine, Hopital Cochin, Paris, France, ¹¹The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel, ¹²The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Ramat Gan, Israel
Background/Purpose: Autoantibodies targeting Domain-1(D1) of beta-2-glycoprotein-1(β2GP1) are common among patients with the antiphospholipid syndrome (APS)1. However, few studies assessed their clinical relevance and correlation with…
Abstract Number: 2 • 2013 ACR/ARHP Annual Meeting
Charaterization Of Micrornas Involved In The Regulation Of Atherotrhombosis In Antiphospholipid Syndrome and Systemic Lupus Erythematosus
Chary Lopez-Pedrera¹, Patricia Ruiz-Limon¹, Raul Teruel², Ángeles Aguirre Zamorano¹, Rosario M. Carretero-Prieto¹, Nuria Barbarroja¹, Antonio Rodriguez-Ariza³, Eduardo Collantes-Estevez⁴, Rocio gonzalez-Conejero², Constantino Martinez², Mª Jose Cuadrado⁵ and Carlos Perez-Sanchez¹, ¹Rheumatology Unit, IMIBIC-Reina Sofia University Hospital, Cordoba, Spain, ²Regional Centre for Blood Donation, University of Murcia, Murcia, Spain, ³Oncology Service and Research Unit, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ⁴Rheumatology, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ⁵Lupus Research Unit, The Rayne Institute, London, United Kingdom
Background/Purpose: miRNAs are key players in pathophysiological processes, but no previous studies have investigated their asscociation with the cardiovascular and atherothrombotic risks observed in primary…
Abstract Number: 3 • 2013 ACR/ARHP Annual Meeting
The Global Antiphospholipid Syndrome Score (GAPSS) In Primary APS
Savino Sciascia¹, Giovanni Sanna², Veronica Murru³, Dario Roccatello¹, Munther A. Khamashta⁴ and Maria Laura Bertolaccini³, ¹Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ²Louise Coote Lupus Unit, St. Thomas' Hospital, London, United Kingdom, ³Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, ⁴Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom
Background/Purpose: Antiphospholipid Syndrome (APS) is a heterogeneous entity with a wide variation in clinical course and laboratory profile. We aimed to evaluate the clinical utility…
Abstract Number: 4 • 2013 ACR/ARHP Annual Meeting
Proteomic Analyses Of Monocyte Responses To IgG From Patients With Antiphospholipid Syndrome
Vera M. Ripoll¹, Anastasia Lambrianides², Wendy Heywood³, Anisur Rahman⁴, Yiannis Ioannou⁵ and Ian Giles⁶, ¹Centre for Rheumatology, Rayne Institute, 4th floor, Centre for Rheumatology, University College London, London, United Kingdom, ²Centre for Rheumatology Research, University College London, London, United Kingdom, ³Institute of Child Health, University College London, London, United Kingdom, ⁴Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom, ⁵Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁶Centre for Rheumatology, Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disorder characterised by recurrent vascular thrombosis (VT) and/or pregnancy morbidity (PM) caused by antiphospholipid antibodies (aPL). Whilst aPL are known…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].